nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2A6—esophageal cancer	0.408	0.729	CbGaD
Buprenorphine—ABCB1—esophageal cancer	0.152	0.271	CbGaD
Buprenorphine—ABCG2—Carboplatin—esophageal cancer	0.0561	0.259	CbGbCtD
Buprenorphine—ABCG2—Cisplatin—esophageal cancer	0.0479	0.221	CbGbCtD
Buprenorphine—CYP2C9—Capecitabine—esophageal cancer	0.0354	0.163	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—esophageal cancer	0.0311	0.144	CbGbCtD
Buprenorphine—CYP2C9—Cisplatin—esophageal cancer	0.0178	0.0821	CbGbCtD
Buprenorphine—ABCB1—Cisplatin—esophageal cancer	0.0173	0.0797	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—esophageal cancer	0.0112	0.0518	CbGbCtD
Buprenorphine—Naloxone—TLR4—esophageal cancer	0.0028	0.78	CrCbGaD
Buprenorphine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000463	0.00541	CcSEcCtD
Buprenorphine—Breast disorder—Cisplatin—esophageal cancer	0.000458	0.00535	CcSEcCtD
Buprenorphine—Naltrexone—ABCB1—esophageal cancer	0.000457	0.127	CrCbGaD
Buprenorphine—Cramp muscle—Cisplatin—esophageal cancer	0.000457	0.00533	CcSEcCtD
Buprenorphine—Nasopharyngitis—Cisplatin—esophageal cancer	0.000453	0.0053	CcSEcCtD
Buprenorphine—Apnoea—Methotrexate—esophageal cancer	0.000452	0.00528	CcSEcCtD
Buprenorphine—Mental disability—Capecitabine—esophageal cancer	0.000447	0.00522	CcSEcCtD
Buprenorphine—Ear pain—Capecitabine—esophageal cancer	0.000438	0.00512	CcSEcCtD
Buprenorphine—Sleep disorder—Capecitabine—esophageal cancer	0.000432	0.00504	CcSEcCtD
Buprenorphine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00042	0.00491	CcSEcCtD
Buprenorphine—Dysarthria—Methotrexate—esophageal cancer	0.000405	0.00473	CcSEcCtD
Buprenorphine—Libido decreased—Capecitabine—esophageal cancer	0.000403	0.00471	CcSEcCtD
Buprenorphine—Hot flush—Capecitabine—esophageal cancer	0.0004	0.00467	CcSEcCtD
Buprenorphine—Menopausal symptoms—Capecitabine—esophageal cancer	0.000396	0.00463	CcSEcCtD
Buprenorphine—Inflammation—Methotrexate—esophageal cancer	0.000395	0.00462	CcSEcCtD
Buprenorphine—Respiratory failure—Methotrexate—esophageal cancer	0.00039	0.00456	CcSEcCtD
Buprenorphine—Lethargy—Capecitabine—esophageal cancer	0.000381	0.00445	CcSEcCtD
Buprenorphine—Conjunctivitis—Cisplatin—esophageal cancer	0.00038	0.00444	CcSEcCtD
Buprenorphine—Osteoarthritis—Capecitabine—esophageal cancer	0.000374	0.00437	CcSEcCtD
Buprenorphine—Pain in extremity—Capecitabine—esophageal cancer	0.000374	0.00437	CcSEcCtD
Buprenorphine—Diplopia—Capecitabine—esophageal cancer	0.000374	0.00437	CcSEcCtD
Buprenorphine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000371	0.00433	CcSEcCtD
Buprenorphine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00037	0.00432	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00037	0.00432	CcSEcCtD
Buprenorphine—Migraine—Capecitabine—esophageal cancer	0.000368	0.0043	CcSEcCtD
Buprenorphine—Face oedema—Capecitabine—esophageal cancer	0.000361	0.00421	CcSEcCtD
Buprenorphine—Bradycardia—Cisplatin—esophageal cancer	0.000357	0.00417	CcSEcCtD
Buprenorphine—Urinary retention—Capecitabine—esophageal cancer	0.000355	0.00415	CcSEcCtD
Buprenorphine—Mood swings—Capecitabine—esophageal cancer	0.000354	0.00414	CcSEcCtD
Buprenorphine—Coma—Methotrexate—esophageal cancer	0.00035	0.00409	CcSEcCtD
Buprenorphine—Dehydration—Capecitabine—esophageal cancer	0.000348	0.00406	CcSEcCtD
Buprenorphine—Urinary tract disorder—Cisplatin—esophageal cancer	0.000346	0.00405	CcSEcCtD
Buprenorphine—Connective tissue disorder—Cisplatin—esophageal cancer	0.000345	0.00403	CcSEcCtD
Buprenorphine—Urethral disorder—Cisplatin—esophageal cancer	0.000344	0.00402	CcSEcCtD
Buprenorphine—Dry skin—Capecitabine—esophageal cancer	0.000343	0.004	CcSEcCtD
Buprenorphine—Abdominal pain upper—Capecitabine—esophageal cancer	0.000341	0.00399	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000341	0.00399	CcSEcCtD
Buprenorphine—Visual impairment—Cisplatin—esophageal cancer	0.000338	0.00395	CcSEcCtD
Buprenorphine—Breast disorder—Capecitabine—esophageal cancer	0.000338	0.00394	CcSEcCtD
Buprenorphine—Nasopharyngitis—Capecitabine—esophageal cancer	0.000334	0.0039	CcSEcCtD
Buprenorphine—Naloxone—ABCB1—esophageal cancer	0.000334	0.0929	CrCbGaD
Buprenorphine—Muscular weakness—Capecitabine—esophageal cancer	0.00033	0.00385	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00033	0.00385	CcSEcCtD
Buprenorphine—Eye disorder—Cisplatin—esophageal cancer	0.000328	0.00383	CcSEcCtD
Buprenorphine—Tinnitus—Cisplatin—esophageal cancer	0.000327	0.00382	CcSEcCtD
Buprenorphine—Flushing—Cisplatin—esophageal cancer	0.000326	0.0038	CcSEcCtD
Buprenorphine—Cardiac disorder—Cisplatin—esophageal cancer	0.000326	0.0038	CcSEcCtD
Buprenorphine—Abdominal distension—Capecitabine—esophageal cancer	0.000325	0.0038	CcSEcCtD
Buprenorphine—Dysphagia—Capecitabine—esophageal cancer	0.000323	0.00377	CcSEcCtD
Buprenorphine—Influenza—Capecitabine—esophageal cancer	0.000323	0.00377	CcSEcCtD
Buprenorphine—Asthma—Capecitabine—esophageal cancer	0.000323	0.00377	CcSEcCtD
Buprenorphine—Bronchospasm—Capecitabine—esophageal cancer	0.000318	0.00371	CcSEcCtD
Buprenorphine—Immune system disorder—Cisplatin—esophageal cancer	0.000317	0.0037	CcSEcCtD
Buprenorphine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000316	0.00369	CcSEcCtD
Buprenorphine—Angina pectoris—Capecitabine—esophageal cancer	0.000315	0.00368	CcSEcCtD
Buprenorphine—Bronchitis—Capecitabine—esophageal cancer	0.000311	0.00363	CcSEcCtD
Buprenorphine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00031	0.00362	CcSEcCtD
Buprenorphine—Malnutrition—Cisplatin—esophageal cancer	0.000305	0.00357	CcSEcCtD
Buprenorphine—Erythema—Cisplatin—esophageal cancer	0.000305	0.00357	CcSEcCtD
Buprenorphine—Flatulence—Cisplatin—esophageal cancer	0.000301	0.00351	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0003	0.00351	CcSEcCtD
Buprenorphine—Visual disturbance—Methotrexate—esophageal cancer	0.000294	0.00343	CcSEcCtD
Buprenorphine—Muscle spasms—Cisplatin—esophageal cancer	0.000294	0.00343	CcSEcCtD
Buprenorphine—Weight decreased—Capecitabine—esophageal cancer	0.000292	0.00341	CcSEcCtD
Buprenorphine—Infestation NOS—Capecitabine—esophageal cancer	0.000288	0.00336	CcSEcCtD
Buprenorphine—Infestation—Capecitabine—esophageal cancer	0.000288	0.00336	CcSEcCtD
Buprenorphine—Vision blurred—Cisplatin—esophageal cancer	0.000288	0.00336	CcSEcCtD
Buprenorphine—Depression—Capecitabine—esophageal cancer	0.000287	0.00335	CcSEcCtD
Buprenorphine—Tremor—Cisplatin—esophageal cancer	0.000286	0.00334	CcSEcCtD
Buprenorphine—Lethargy—Methotrexate—esophageal cancer	0.000284	0.00332	CcSEcCtD
Buprenorphine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000283	0.00331	CcSEcCtD
Buprenorphine—Conjunctivitis—Capecitabine—esophageal cancer	0.00028	0.00327	CcSEcCtD
Buprenorphine—Urinary tract infection—Capecitabine—esophageal cancer	0.00028	0.00327	CcSEcCtD
Buprenorphine—Osteoarthritis—Methotrexate—esophageal cancer	0.000278	0.00325	CcSEcCtD
Buprenorphine—Malaise—Cisplatin—esophageal cancer	0.000275	0.00322	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000272	0.00318	CcSEcCtD
Buprenorphine—Convulsion—Cisplatin—esophageal cancer	0.000265	0.00309	CcSEcCtD
Buprenorphine—Mood swings—Methotrexate—esophageal cancer	0.000264	0.00308	CcSEcCtD
Buprenorphine—Bradycardia—Capecitabine—esophageal cancer	0.000263	0.00307	CcSEcCtD
Buprenorphine—Myalgia—Cisplatin—esophageal cancer	0.00026	0.00304	CcSEcCtD
Buprenorphine—Rhinitis—Capecitabine—esophageal cancer	0.000259	0.00303	CcSEcCtD
Buprenorphine—Anxiety—Cisplatin—esophageal cancer	0.000259	0.00303	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000258	0.00302	CcSEcCtD
Buprenorphine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000257	0.003	CcSEcCtD
Buprenorphine—Discomfort—Cisplatin—esophageal cancer	0.000257	0.003	CcSEcCtD
Buprenorphine—Pharyngitis—Capecitabine—esophageal cancer	0.000257	0.003	CcSEcCtD
Buprenorphine—Urinary tract disorder—Capecitabine—esophageal cancer	0.000255	0.00298	CcSEcCtD
Buprenorphine—Oedema peripheral—Capecitabine—esophageal cancer	0.000255	0.00297	CcSEcCtD
Buprenorphine—Connective tissue disorder—Capecitabine—esophageal cancer	0.000254	0.00297	CcSEcCtD
Buprenorphine—Urethral disorder—Capecitabine—esophageal cancer	0.000253	0.00296	CcSEcCtD
Buprenorphine—Breast disorder—Methotrexate—esophageal cancer	0.000251	0.00294	CcSEcCtD
Buprenorphine—Oedema—Cisplatin—esophageal cancer	0.000249	0.00291	CcSEcCtD
Buprenorphine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000249	0.00291	CcSEcCtD
Buprenorphine—Visual impairment—Capecitabine—esophageal cancer	0.000249	0.00291	CcSEcCtD
Buprenorphine—Infection—Cisplatin—esophageal cancer	0.000248	0.00289	CcSEcCtD
Buprenorphine—Nervous system disorder—Cisplatin—esophageal cancer	0.000244	0.00285	CcSEcCtD
Buprenorphine—Tachycardia—Cisplatin—esophageal cancer	0.000243	0.00284	CcSEcCtD
Buprenorphine—Skin disorder—Cisplatin—esophageal cancer	0.000242	0.00283	CcSEcCtD
Buprenorphine—Eye disorder—Capecitabine—esophageal cancer	0.000242	0.00282	CcSEcCtD
Buprenorphine—Tinnitus—Capecitabine—esophageal cancer	0.000241	0.00282	CcSEcCtD
Buprenorphine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000241	0.00281	CcSEcCtD
Buprenorphine—Asthma—Methotrexate—esophageal cancer	0.00024	0.00281	CcSEcCtD
Buprenorphine—Flushing—Capecitabine—esophageal cancer	0.00024	0.0028	CcSEcCtD
Buprenorphine—Cardiac disorder—Capecitabine—esophageal cancer	0.00024	0.0028	CcSEcCtD
Buprenorphine—Anorexia—Cisplatin—esophageal cancer	0.000238	0.00277	CcSEcCtD
Buprenorphine—Angiopathy—Capecitabine—esophageal cancer	0.000235	0.00274	CcSEcCtD
Buprenorphine—Immune system disorder—Capecitabine—esophageal cancer	0.000234	0.00273	CcSEcCtD
Buprenorphine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000233	0.00272	CcSEcCtD
Buprenorphine—Hypotension—Cisplatin—esophageal cancer	0.000233	0.00272	CcSEcCtD
Buprenorphine—Chills—Capecitabine—esophageal cancer	0.000232	0.00271	CcSEcCtD
Buprenorphine—Abdominal discomfort—Methotrexate—esophageal cancer	0.000231	0.00269	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000227	0.00265	CcSEcCtD
Buprenorphine—Mental disorder—Capecitabine—esophageal cancer	0.000227	0.00265	CcSEcCtD
Buprenorphine—Erythema—Capecitabine—esophageal cancer	0.000225	0.00263	CcSEcCtD
Buprenorphine—Malnutrition—Capecitabine—esophageal cancer	0.000225	0.00263	CcSEcCtD
Buprenorphine—Paraesthesia—Cisplatin—esophageal cancer	0.000224	0.00261	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000223	0.00261	CcSEcCtD
Buprenorphine—Dyspnoea—Cisplatin—esophageal cancer	0.000222	0.00259	CcSEcCtD
Buprenorphine—Flatulence—Capecitabine—esophageal cancer	0.000222	0.00259	CcSEcCtD
Buprenorphine—Dysgeusia—Capecitabine—esophageal cancer	0.00022	0.00257	CcSEcCtD
Buprenorphine—Back pain—Capecitabine—esophageal cancer	0.000218	0.00254	CcSEcCtD
Buprenorphine—Decreased appetite—Cisplatin—esophageal cancer	0.000217	0.00253	CcSEcCtD
Buprenorphine—Muscle spasms—Capecitabine—esophageal cancer	0.000216	0.00253	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000215	0.00251	CcSEcCtD
Buprenorphine—Infestation—Methotrexate—esophageal cancer	0.000214	0.0025	CcSEcCtD
Buprenorphine—Infestation NOS—Methotrexate—esophageal cancer	0.000214	0.0025	CcSEcCtD
Buprenorphine—Depression—Methotrexate—esophageal cancer	0.000214	0.0025	CcSEcCtD
Buprenorphine—Pain—Cisplatin—esophageal cancer	0.000213	0.00249	CcSEcCtD
Buprenorphine—Vision blurred—Capecitabine—esophageal cancer	0.000212	0.00248	CcSEcCtD
Buprenorphine—Tremor—Capecitabine—esophageal cancer	0.000211	0.00246	CcSEcCtD
Buprenorphine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000209	0.00244	CcSEcCtD
Buprenorphine—Conjunctivitis—Methotrexate—esophageal cancer	0.000208	0.00243	CcSEcCtD
Buprenorphine—Sweating—Methotrexate—esophageal cancer	0.000206	0.0024	CcSEcCtD
Buprenorphine—Feeling abnormal—Cisplatin—esophageal cancer	0.000205	0.0024	CcSEcCtD
Buprenorphine—Malaise—Capecitabine—esophageal cancer	0.000203	0.00237	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000203	0.00237	CcSEcCtD
Buprenorphine—Vertigo—Capecitabine—esophageal cancer	0.000202	0.00236	CcSEcCtD
Buprenorphine—Syncope—Capecitabine—esophageal cancer	0.000202	0.00236	CcSEcCtD
Buprenorphine—Palpitations—Capecitabine—esophageal cancer	0.000199	0.00232	CcSEcCtD
Buprenorphine—Loss of consciousness—Capecitabine—esophageal cancer	0.000198	0.00231	CcSEcCtD
Buprenorphine—Body temperature increased—Cisplatin—esophageal cancer	0.000197	0.0023	CcSEcCtD
Buprenorphine—Cough—Capecitabine—esophageal cancer	0.000196	0.00229	CcSEcCtD
Buprenorphine—Hypertension—Capecitabine—esophageal cancer	0.000194	0.00227	CcSEcCtD
Buprenorphine—Myalgia—Capecitabine—esophageal cancer	0.000192	0.00224	CcSEcCtD
Buprenorphine—Arthralgia—Capecitabine—esophageal cancer	0.000192	0.00224	CcSEcCtD
Buprenorphine—Chest pain—Capecitabine—esophageal cancer	0.000192	0.00224	CcSEcCtD
Buprenorphine—Pharyngitis—Methotrexate—esophageal cancer	0.000191	0.00223	CcSEcCtD
Buprenorphine—Anxiety—Capecitabine—esophageal cancer	0.000191	0.00223	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00019	0.00222	CcSEcCtD
Buprenorphine—Urinary tract disorder—Methotrexate—esophageal cancer	0.00019	0.00222	CcSEcCtD
Buprenorphine—Discomfort—Capecitabine—esophageal cancer	0.000189	0.00221	CcSEcCtD
Buprenorphine—Urethral disorder—Methotrexate—esophageal cancer	0.000189	0.0022	CcSEcCtD
Buprenorphine—Dry mouth—Capecitabine—esophageal cancer	0.000187	0.00219	CcSEcCtD
Buprenorphine—Visual impairment—Methotrexate—esophageal cancer	0.000185	0.00217	CcSEcCtD
Buprenorphine—Confusional state—Capecitabine—esophageal cancer	0.000185	0.00216	CcSEcCtD
Buprenorphine—Oedema—Capecitabine—esophageal cancer	0.000184	0.00215	CcSEcCtD
Buprenorphine—Hypersensitivity—Cisplatin—esophageal cancer	0.000184	0.00214	CcSEcCtD
Buprenorphine—Infection—Capecitabine—esophageal cancer	0.000182	0.00213	CcSEcCtD
Buprenorphine—Shock—Capecitabine—esophageal cancer	0.000181	0.00211	CcSEcCtD
Buprenorphine—Nervous system disorder—Capecitabine—esophageal cancer	0.00018	0.0021	CcSEcCtD
Buprenorphine—Eye disorder—Methotrexate—esophageal cancer	0.00018	0.0021	CcSEcCtD
Buprenorphine—Tinnitus—Methotrexate—esophageal cancer	0.000179	0.0021	CcSEcCtD
Buprenorphine—Tachycardia—Capecitabine—esophageal cancer	0.000179	0.00209	CcSEcCtD
Buprenorphine—Asthenia—Cisplatin—esophageal cancer	0.000179	0.00209	CcSEcCtD
Buprenorphine—Cardiac disorder—Methotrexate—esophageal cancer	0.000179	0.00209	CcSEcCtD
Buprenorphine—Skin disorder—Capecitabine—esophageal cancer	0.000178	0.00208	CcSEcCtD
Buprenorphine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000178	0.00207	CcSEcCtD
Buprenorphine—Anorexia—Capecitabine—esophageal cancer	0.000175	0.00205	CcSEcCtD
Buprenorphine—Angiopathy—Methotrexate—esophageal cancer	0.000175	0.00204	CcSEcCtD
Buprenorphine—Immune system disorder—Methotrexate—esophageal cancer	0.000174	0.00203	CcSEcCtD
Buprenorphine—Mediastinal disorder—Methotrexate—esophageal cancer	0.000173	0.00203	CcSEcCtD
Buprenorphine—Chills—Methotrexate—esophageal cancer	0.000173	0.00202	CcSEcCtD
Buprenorphine—Hypotension—Capecitabine—esophageal cancer	0.000172	0.002	CcSEcCtD
Buprenorphine—Diarrhoea—Cisplatin—esophageal cancer	0.00017	0.00199	CcSEcCtD
Buprenorphine—Mental disorder—Methotrexate—esophageal cancer	0.000169	0.00197	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—esophageal cancer	0.000168	0.00196	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—esophageal cancer	0.000168	0.00196	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000167	0.00195	CcSEcCtD
Buprenorphine—Insomnia—Capecitabine—esophageal cancer	0.000166	0.00194	CcSEcCtD
Buprenorphine—Paraesthesia—Capecitabine—esophageal cancer	0.000165	0.00193	CcSEcCtD
Buprenorphine—Dysgeusia—Methotrexate—esophageal cancer	0.000164	0.00192	CcSEcCtD
Buprenorphine—Dyspnoea—Capecitabine—esophageal cancer	0.000164	0.00191	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—esophageal cancer	0.000162	0.00189	CcSEcCtD
Buprenorphine—Dyspepsia—Capecitabine—esophageal cancer	0.000162	0.00189	CcSEcCtD
Buprenorphine—Decreased appetite—Capecitabine—esophageal cancer	0.00016	0.00187	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000159	0.00185	CcSEcCtD
Buprenorphine—Vomiting—Cisplatin—esophageal cancer	0.000158	0.00185	CcSEcCtD
Buprenorphine—Fatigue—Capecitabine—esophageal cancer	0.000158	0.00185	CcSEcCtD
Buprenorphine—Vision blurred—Methotrexate—esophageal cancer	0.000158	0.00184	CcSEcCtD
Buprenorphine—Rash—Cisplatin—esophageal cancer	0.000157	0.00184	CcSEcCtD
Buprenorphine—Pain—Capecitabine—esophageal cancer	0.000157	0.00183	CcSEcCtD
Buprenorphine—Constipation—Capecitabine—esophageal cancer	0.000157	0.00183	CcSEcCtD
Buprenorphine—Dermatitis—Cisplatin—esophageal cancer	0.000157	0.00183	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000155	0.00182	CcSEcCtD
Buprenorphine—Feeling abnormal—Capecitabine—esophageal cancer	0.000151	0.00177	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—esophageal cancer	0.000151	0.00176	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—esophageal cancer	0.000151	0.00176	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00015	0.00175	CcSEcCtD
Buprenorphine—Nausea—Cisplatin—esophageal cancer	0.000148	0.00173	CcSEcCtD
Buprenorphine—Cough—Methotrexate—esophageal cancer	0.000146	0.00171	CcSEcCtD
Buprenorphine—Urticaria—Capecitabine—esophageal cancer	0.000146	0.0017	CcSEcCtD
Buprenorphine—Abdominal pain—Capecitabine—esophageal cancer	0.000145	0.0017	CcSEcCtD
Buprenorphine—Body temperature increased—Capecitabine—esophageal cancer	0.000145	0.0017	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—esophageal cancer	0.000145	0.0017	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—esophageal cancer	0.000143	0.00167	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—esophageal cancer	0.000143	0.00167	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—esophageal cancer	0.000143	0.00167	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000142	0.00165	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—esophageal cancer	0.000141	0.00165	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—esophageal cancer	0.000138	0.00161	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000137	0.0016	CcSEcCtD
Buprenorphine—Infection—Methotrexate—esophageal cancer	0.000136	0.00159	CcSEcCtD
Buprenorphine—Hypersensitivity—Capecitabine—esophageal cancer	0.000135	0.00158	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—esophageal cancer	0.000134	0.00157	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—esophageal cancer	0.000133	0.00155	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000132	0.00154	CcSEcCtD
Buprenorphine—Asthenia—Capecitabine—esophageal cancer	0.000132	0.00154	CcSEcCtD
Buprenorphine—Anorexia—Methotrexate—esophageal cancer	0.00013	0.00152	CcSEcCtD
Buprenorphine—Pruritus—Capecitabine—esophageal cancer	0.00013	0.00152	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—esophageal cancer	0.000128	0.00149	CcSEcCtD
Buprenorphine—Diarrhoea—Capecitabine—esophageal cancer	0.000126	0.00147	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000125	0.00146	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—esophageal cancer	0.000124	0.00144	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—esophageal cancer	0.000123	0.00143	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—esophageal cancer	0.000122	0.00142	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—esophageal cancer	0.000122	0.00142	CcSEcCtD
Buprenorphine—Dizziness—Capecitabine—esophageal cancer	0.000121	0.00142	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—esophageal cancer	0.00012	0.00141	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—esophageal cancer	0.000119	0.00139	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000118	0.00138	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—esophageal cancer	0.000118	0.00138	CcSEcCtD
Buprenorphine—Pain—Methotrexate—esophageal cancer	0.000117	0.00137	CcSEcCtD
Buprenorphine—Vomiting—Capecitabine—esophageal cancer	0.000117	0.00136	CcSEcCtD
Buprenorphine—Rash—Capecitabine—esophageal cancer	0.000116	0.00135	CcSEcCtD
Buprenorphine—Dermatitis—Capecitabine—esophageal cancer	0.000116	0.00135	CcSEcCtD
Buprenorphine—Headache—Capecitabine—esophageal cancer	0.000115	0.00134	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—esophageal cancer	0.000113	0.00132	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000112	0.00131	CcSEcCtD
Buprenorphine—Nausea—Capecitabine—esophageal cancer	0.000109	0.00127	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—esophageal cancer	0.000109	0.00127	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—esophageal cancer	0.000108	0.00126	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—esophageal cancer	0.000108	0.00126	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—esophageal cancer	0.000101	0.00118	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—esophageal cancer	9.81e-05	0.00115	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—esophageal cancer	9.67e-05	0.00113	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—esophageal cancer	9.36e-05	0.00109	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—esophageal cancer	9.04e-05	0.00106	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—esophageal cancer	8.69e-05	0.00102	CcSEcCtD
Buprenorphine—Rash—Methotrexate—esophageal cancer	8.62e-05	0.00101	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—esophageal cancer	8.61e-05	0.00101	CcSEcCtD
Buprenorphine—Headache—Methotrexate—esophageal cancer	8.57e-05	0.001	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—esophageal cancer	8.12e-05	0.000949	CcSEcCtD
Buprenorphine—CYP2C9—Metabolism—TPI1—esophageal cancer	1.15e-05	8.61e-05	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—esophageal cancer	1.15e-05	8.61e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ABCB1—esophageal cancer	1.15e-05	8.6e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.14e-05	8.52e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GAPDH—esophageal cancer	1.14e-05	8.51e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.14e-05	8.49e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CRABP1—esophageal cancer	1.13e-05	8.43e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SMAD4—esophageal cancer	1.12e-05	8.36e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.11e-05	8.33e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NOTCH1—esophageal cancer	1.11e-05	8.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.11e-05	8.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GNG7—esophageal cancer	1.1e-05	8.22e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.1e-05	8.22e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.1e-05	8.21e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.1e-05	8.21e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMP—esophageal cancer	1.09e-05	8.14e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.09e-05	8.11e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HIF1A—esophageal cancer	1.08e-05	8.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.08e-05	8.08e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CA2—esophageal cancer	1.08e-05	8.06e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GNG7—esophageal cancer	1.07e-05	8.02e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.07e-05	8.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.06e-05	7.95e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.06e-05	7.95e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.06e-05	7.92e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.06e-05	7.88e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.05e-05	7.88e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KDR—esophageal cancer	1.04e-05	7.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—NOS3—esophageal cancer	1.04e-05	7.74e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.03e-05	7.73e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.03e-05	7.72e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALDH2—esophageal cancer	1.03e-05	7.7e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.03e-05	7.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ENO1—esophageal cancer	1.03e-05	7.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PSME1—esophageal cancer	1.01e-05	7.58e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PSME2—esophageal cancer	1.01e-05	7.58e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GNG7—esophageal cancer	1.01e-05	7.56e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP1B1—esophageal cancer	1.01e-05	7.55e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CREBBP—esophageal cancer	1.01e-05	7.54e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALDH2—esophageal cancer	1.01e-05	7.52e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PLCE1—esophageal cancer	1e-05	7.5e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADH7—esophageal cancer	1e-05	7.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GNG7—esophageal cancer	1e-05	7.49e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—EGFR—esophageal cancer	9.92e-06	7.41e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TPI1—esophageal cancer	9.85e-06	7.36e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTO1—esophageal cancer	9.85e-06	7.36e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTT1—esophageal cancer	9.8e-06	7.32e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NOTCH1—esophageal cancer	9.76e-06	7.29e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP2A6—esophageal cancer	9.69e-06	7.24e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.65e-06	7.21e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTT1—esophageal cancer	9.57e-06	7.15e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP19A1—esophageal cancer	9.5e-06	7.1e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALDH2—esophageal cancer	9.48e-06	7.08e-05	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	9.48e-06	7.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—esophageal cancer	9.48e-06	7.08e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP2A6—esophageal cancer	9.46e-06	7.07e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALDOB—esophageal cancer	9.45e-06	7.06e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALDH2—esophageal cancer	9.4e-06	7.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS1—esophageal cancer	9.19e-06	6.86e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ENO1—esophageal cancer	9.19e-06	6.86e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HIF1A—esophageal cancer	9.16e-06	6.84e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CREBBP—esophageal cancer	9.15e-06	6.83e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GAPDH—esophageal cancer	9.09e-06	6.79e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PSME1—esophageal cancer	9.05e-06	6.76e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PSME2—esophageal cancer	9.05e-06	6.76e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NOS3—esophageal cancer	9.04e-06	6.75e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTT1—esophageal cancer	9.02e-06	6.74e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CRABP1—esophageal cancer	9.01e-06	6.73e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ENO1—esophageal cancer	8.97e-06	6.7e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS1—esophageal cancer	8.97e-06	6.7e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	8.96e-06	6.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTT1—esophageal cancer	8.94e-06	6.68e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	8.91e-06	6.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.86e-06	6.62e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CREBBP—esophageal cancer	8.85e-06	6.61e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	8.84e-06	6.6e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PSME1—esophageal cancer	8.84e-06	6.6e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PSME2—esophageal cancer	8.84e-06	6.6e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.8e-06	6.58e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.8e-06	6.57e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KDR—esophageal cancer	8.76e-06	6.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP1B1—esophageal cancer	8.75e-06	6.54e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—esophageal cancer	8.7e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—HMOX1—esophageal cancer	8.67e-06	6.48e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CA—esophageal cancer	8.61e-06	6.43e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GNG7—esophageal cancer	8.57e-06	6.4e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB2—esophageal cancer	8.45e-06	6.31e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ENO1—esophageal cancer	8.45e-06	6.31e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS1—esophageal cancer	8.45e-06	6.31e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMP—esophageal cancer	8.41e-06	6.28e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ENO1—esophageal cancer	8.38e-06	6.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS1—esophageal cancer	8.38e-06	6.26e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PSME1—esophageal cancer	8.33e-06	6.22e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PSME2—esophageal cancer	8.33e-06	6.22e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ABCB1—esophageal cancer	8.32e-06	6.22e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.31e-06	6.21e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PSME1—esophageal cancer	8.25e-06	6.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PSME2—esophageal cancer	8.25e-06	6.17e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NOTCH1—esophageal cancer	8.25e-06	6.16e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP19A1—esophageal cancer	8.23e-06	6.15e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—NOS3—esophageal cancer	8.19e-06	6.12e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	8.18e-06	6.11e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALDH2—esophageal cancer	8.03e-06	6e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.97e-06	5.95e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NOS3—esophageal cancer	7.92e-06	5.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.91e-06	5.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—EP300—esophageal cancer	7.88e-06	5.89e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	7.81e-06	5.84e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CREBBP—esophageal cancer	7.76e-06	5.8e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CREBBP—esophageal cancer	7.69e-06	5.75e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTT1—esophageal cancer	7.64e-06	5.71e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP1B1—esophageal cancer	7.62e-06	5.7e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.6e-06	5.68e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TPI1—esophageal cancer	7.6e-06	5.68e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	7.55e-06	5.64e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—esophageal cancer	7.55e-06	5.64e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.52e-06	5.62e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—HMOX1—esophageal cancer	7.51e-06	5.61e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—esophageal cancer	7.49e-06	5.6e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CREBBP—esophageal cancer	7.48e-06	5.59e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—esophageal cancer	7.47e-06	5.58e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—esophageal cancer	7.41e-06	5.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.37e-06	5.5e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—esophageal cancer	7.35e-06	5.49e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	7.34e-06	5.49e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALDOB—esophageal cancer	7.29e-06	5.45e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1A—esophageal cancer	7.22e-06	5.4e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.21e-06	5.39e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ABCB1—esophageal cancer	7.21e-06	5.38e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	7.18e-06	5.37e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP19A1—esophageal cancer	7.17e-06	5.36e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS1—esophageal cancer	7.16e-06	5.35e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ENO1—esophageal cancer	7.16e-06	5.35e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	7.12e-06	5.32e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PSME2—esophageal cancer	7.05e-06	5.27e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PSME1—esophageal cancer	7.05e-06	5.27e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CREBBP—esophageal cancer	7.05e-06	5.27e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	7.02e-06	5.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GAPDH—esophageal cancer	7.02e-06	5.24e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.95e-06	5.2e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—NOS3—esophageal cancer	6.95e-06	5.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—NOS3—esophageal cancer	6.89e-06	5.15e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EP300—esophageal cancer	6.87e-06	5.14e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	6.75e-06	5.05e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—HMOX1—esophageal cancer	6.7e-06	5.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	6.7e-06	5e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NOS3—esophageal cancer	6.7e-06	5e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GNG7—esophageal cancer	6.61e-06	4.94e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.57e-06	4.91e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—esophageal cancer	6.55e-06	4.89e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—HMOX1—esophageal cancer	6.54e-06	4.89e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—esophageal cancer	6.43e-06	4.81e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—esophageal cancer	6.38e-06	4.77e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—esophageal cancer	6.36e-06	4.75e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1A—esophageal cancer	6.33e-06	4.73e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—NOS3—esophageal cancer	6.31e-06	4.72e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—esophageal cancer	6.3e-06	4.71e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—esophageal cancer	6.26e-06	4.68e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—EP300—esophageal cancer	6.23e-06	4.65e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.2e-06	4.63e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.16e-06	4.61e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.16e-06	4.6e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HMOX1—esophageal cancer	6.11e-06	4.57e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	6.09e-06	4.55e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EP300—esophageal cancer	6.03e-06	4.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.99e-06	4.48e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—esophageal cancer	5.99e-06	4.47e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.92e-06	4.42e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.9e-06	4.4e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—esophageal cancer	5.87e-06	4.38e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—esophageal cancer	5.86e-06	4.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—esophageal cancer	5.83e-06	4.36e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.83e-06	4.35e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—esophageal cancer	5.77e-06	4.31e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.72e-06	4.28e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CREBBP—esophageal cancer	5.56e-06	4.15e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—esophageal cancer	5.53e-06	4.13e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.52e-06	4.13e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO1—esophageal cancer	5.52e-06	4.13e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.45e-06	4.07e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PSME2—esophageal cancer	5.44e-06	4.07e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PSME1—esophageal cancer	5.44e-06	4.07e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1A—esophageal cancer	5.35e-06	4e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—EP300—esophageal cancer	5.29e-06	3.95e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—esophageal cancer	5.25e-06	3.92e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—EP300—esophageal cancer	5.24e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.22e-06	3.9e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—esophageal cancer	5.14e-06	3.84e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.12e-06	3.83e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EP300—esophageal cancer	5.09e-06	3.81e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—esophageal cancer	5.08e-06	3.8e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.01e-06	3.74e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NOS3—esophageal cancer	4.98e-06	3.72e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—esophageal cancer	4.92e-06	3.67e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.86e-06	3.63e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CREBBP—esophageal cancer	4.82e-06	3.6e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—EP300—esophageal cancer	4.8e-06	3.59e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.7e-06	3.51e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—esophageal cancer	4.61e-06	3.44e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—esophageal cancer	4.55e-06	3.4e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—esophageal cancer	4.46e-06	3.33e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—esophageal cancer	4.44e-06	3.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.43e-06	3.31e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.42e-06	3.3e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—esophageal cancer	4.34e-06	3.24e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—esophageal cancer	4.31e-06	3.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NOS3—esophageal cancer	4.31e-06	3.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CREBBP—esophageal cancer	4.3e-06	3.21e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CREBBP—esophageal cancer	4.2e-06	3.14e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.03e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.95e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—esophageal cancer	3.94e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.92e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—esophageal cancer	3.91e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—esophageal cancer	3.88e-06	2.9e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.87e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NOS3—esophageal cancer	3.85e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.79e-06	2.83e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—EP300—esophageal cancer	3.79e-06	2.83e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—esophageal cancer	3.77e-06	2.82e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NOS3—esophageal cancer	3.76e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—esophageal cancer	3.65e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—esophageal cancer	3.55e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NOS3—esophageal cancer	3.54e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—esophageal cancer	3.52e-06	2.63e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NOS3—esophageal cancer	3.51e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—esophageal cancer	3.44e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.35e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—EP300—esophageal cancer	3.28e-06	2.45e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.24e-06	2.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.21e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NOS3—esophageal cancer	3e-06	2.24e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—EP300—esophageal cancer	2.93e-06	2.19e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—EP300—esophageal cancer	2.86e-06	2.14e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—esophageal cancer	2.8e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.74e-06	2.05e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—EP300—esophageal cancer	2.69e-06	2.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—EP300—esophageal cancer	2.67e-06	1.99e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.59e-06	1.93e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—esophageal cancer	2.43e-06	1.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NOS3—esophageal cancer	2.31e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—EP300—esophageal cancer	2.28e-06	1.7e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	2.17e-06	1.62e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.12e-06	1.58e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.11e-06	1.58e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.99e-06	1.49e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.97e-06	1.48e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—EP300—esophageal cancer	1.76e-06	1.32e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.69e-06	1.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.3e-06	9.73e-06	CbGpPWpGaD
